(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.
The three biggest winners today are NANOBIOTIX, VIVORYON, and MYHOTELMATCH.
| Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|
| NANOBIOTIX (NANO.PA) | 3.41 | 105.12% | 2023-05-05 11:00:46 |
| VIVORYON (VVY.AS) | 19.30 | 16.27% | 2023-05-05 11:05:22 |
| MYHOTELMATCH (MHM.PA) | 0.03 | 13.79% | 2023-05-05 11:00:33 |
| SCATEC (SCATC.OL) | 75.40 | 12.2% | 2023-05-05 11:33:28 |
| ADOCIA (ADOC.PA) | 3.19 | 11.34% | 2023-05-05 11:36:12 |
| TEKNA HOLDING (TEKNA.OL) | 6.10 | 10.91% | 2023-05-05 11:34:46 |
| PIERRE VAC BSA ACT (VACBS.PA) | 0.23 | 9.52% | 2023-05-05 11:02:01 |
| VALNEVA (VLA.PA) | 5.68 | 8.48% | 2023-05-05 11:05:45 |
| VOLUE (VOLUE.OL) | 20.05 | 8.38% | 2023-05-05 11:35:12 |
| MEDINCELL (MEDCL.PA) | 8.94 | 7.32% | 2023-05-05 11:00:15 |
The three biggest losers today are NR21, DISRUPTIVE CAP SHA, and SPORTING.
| Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|
| NR21 (NR21.PA) | 86.00 | -14% | 2023-05-05 11:01:12 |
| DISRUPTIVE CAP SHA (DCACS.AS) | 6.70 | -9.46% | 2023-05-05 11:01:48 |
| SPORTING (SCP.LS) | 0.73 | -7.64% | 2023-05-05 11:19:41 |
| SEABIRD EXPLORAT (SBX.OL) | 3.70 | -7.04% | 2023-05-05 11:33:35 |
| HOFSETH BIOCARE (HBC.OL) | 3.20 | -6.98% | 2023-05-05 11:30:30 |
| GEOJUNXION (GOJXN.AS) | 1.11 | -6.36% | 2023-05-05 11:02:41 |
| RALLYE (RAL.PA) | 1.25 | -5.73% | 2023-05-05 11:02:40 |
| BAKKAFROST (BAKKA.OL) | 716.00 | -5.67% | 2023-05-05 11:20:57 |
| CARASENT (CARA.OL) | 14.86 | -5.47% | 2023-05-05 11:21:28 |
| AF GRUPPEN (AFG.OL) | 149.60 | -5.32% | 2023-05-05 11:19:59 |
Winners today
1. NANOBIOTIX (NANO.PA)
105.12% Price Change
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
CAC 40 ended the session with NANOBIOTIX jumping 105.12% to €3.41 on Friday while CAC 40 rose 1.26% to €7,432.93.
Earnings Per Share
As for profitability, NANOBIOTIX has a trailing twelve months EPS of €-1.24.
Volume
Today’s last reported volume for NANOBIOTIX is 1883710 which is 2090.57% above its average volume of 85992.
Moving Average
NANOBIOTIX’s value is above its 50-day moving average of €3.25 and below its 200-day moving average of €3.67.
More news about NANOBIOTIX.
2. VIVORYON (VVY.AS)
16.27% Price Change
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.
AEX-Index ended the session with VIVORYON jumping 16.27% to €19.30 on Friday while AEX-Index jumped 1.25% to €750.48.
Earnings Per Share
As for profitability, VIVORYON has a trailing twelve months EPS of €-0.72.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, VIVORYON’s stock is considered to be oversold (<=20).
Volume
Today’s last reported volume for VIVORYON is 295870 which is 334.34% above its average volume of 68118.
More news about VIVORYON.
3. MYHOTELMATCH (MHM.PA)
13.79% Price Change
MyHotelMatch S.A. engages in the development and exploitation of an online hotel reservation platform based on Artificial Intelligence (AI). It operates as an online travel agency based on the principle of online dating. The company, through its platform, connect a traveler and hotels with online hotel services whose profiles match. The company is based in Biot, France.
CAC 40 ended the session with MYHOTELMATCH jumping 13.79% to €0.03 on Friday while CAC 40 rose 1.26% to €7,432.93.
Earnings Per Share
As for profitability, MYHOTELMATCH has a trailing twelve months EPS of €-0.03.
Yearly Top and Bottom Value
MYHOTELMATCH’s stock is valued at €0.03 at 22:40 EST, way under its 52-week high of €0.04 and way higher than its 52-week low of €0.01.
Volume
Today’s last reported volume for MYHOTELMATCH is 2069810 which is 65.76% below its average volume of 6046440.
Moving Average
MYHOTELMATCH’s value is above its 50-day moving average of €0.03 and way higher than its 200-day moving average of €0.02.
Volatility
MYHOTELMATCH’s last week, last month’s, and last quarter’s current intraday variation average was a negative 11.66%, a negative 1.65%, and a positive 7.37%.
MYHOTELMATCH’s highest amplitude of average volatility was 14.66% (last week), 6.47% (last month), and 7.37% (last quarter).
More news about MYHOTELMATCH.
4. SCATEC (SCATC.OL)
12.2% Price Change
Scatec ASA, together with its subsidiaries, provides renewable energy solutions worldwide. The company operates through Power Production; Services; and Development & Construction segments. It develops, builds, owns, and operates solar, wind, and hydro power plants and storage solutions. The company is also involved in the engineering, procurement, construction, operation, maintenance, and asset management of power plants. It has a total of 4.6 GW in operation and under construction. The company was formerly known as Scatec Solar ASA and changed its name to Scatec ASA in November 2020. Scatec ASA was incorporated in 2007 and is headquartered in Oslo, Norway.
Oslo Børs Benchmark Index_GI ended the session with SCATEC rising 12.2% to €75.40 on Friday, following the last session’s upward trend. Oslo Børs Benchmark Index_GI rose 1.25% to €1,204.54, after three sequential sessions in a row of losses, on what was an all-around bullish trend trading session today.
Earnings Per Share
As for profitability, SCATEC has a trailing twelve months EPS of kr-8.02.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -13.12%.
Yearly Top and Bottom Value
SCATEC’s stock is valued at kr75.40 at 22:40 EST, way under its 52-week high of kr117.00 and way higher than its 52-week low of kr61.76.
Volatility
SCATEC’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.14%, a negative 0.37%, and a positive 2.10%.
SCATEC’s highest amplitude of average volatility was 1.89% (last week), 2.18% (last month), and 2.10% (last quarter).
Moving Average
SCATEC’s worth is higher than its 50-day moving average of kr69.07 and way under its 200-day moving average of kr83.91.
More news about SCATEC.
5. ADOCIA (ADOC.PA)
11.34% Price Change
Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform is designed and developed to optimize the performance of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes bi-hormonal products, which include BioChaperone AsPram, which is a combination of rapid insulin aspart with pramlintide; and BioChaperone Glargine Liraglutidea, which is a fixed combination of insulin glargine with an analogue of the GLP-1 receptor. In addition, the company's preclinical pipeline includes multihormonal products for the treatment of obesity, including BioChaperone GluExe, which is a combination of glucagon and exenatide; PramExe, which is a combination of pramlintide and exenatide; and BioChaperone PramGluExe, which is a triple combination of pramlintide, glucagon and exenatide. It has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. The company was incorporated in 2005 and is headquartered in Lyon, France.
CAC 40 ended the session with ADOCIA jumping 11.34% to €3.19 on Friday while CAC 40 rose 1.26% to €7,432.93.
Earnings Per Share
As for profitability, ADOCIA has a trailing twelve months EPS of €-1.2.
Revenue Growth
Year-on-year quarterly revenue growth grew by 312.1%, now sitting on 13.95M for the twelve trailing months.
Volume
Today’s last reported volume for ADOCIA is 83015 which is 553.91% above its average volume of 12695.
Moving Average
ADOCIA’s worth is way below its 50-day moving average of €3.58 and way under its 200-day moving average of €3.96.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ADOCIA’s stock is considered to be oversold (<=20).
More news about ADOCIA.
6. TEKNA HOLDING (TEKNA.OL)
10.91% Price Change
Tekna Holding ASA develops, manufactures, and sells micro and nano powders, and plasma process solutions in North America, Europe, and Asia. Its material powders and plasma systems are used in various industrial sectors, such as aviation, aerospace, medical, mining and drilling, energy storage, and microelectronics; and applications, such as additive manufacturing, metal injection molding, thermal spray, and hot isostatic pressing. The company was founded in 1990 and is headquartered in Sherbrooke, Canada. Tekna Holding ASA is a subsidiary of Arendals Fossekompani ASA.
Oslo Børs Benchmark Index_GI ended the session with TEKNA HOLDING jumping 10.91% to €6.10 on Friday while Oslo Børs Benchmark Index_GI jumped 1.25% to €1,204.54.
Earnings Per Share
As for profitability, TEKNA HOLDING has a trailing twelve months EPS of kr-1.28.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -34.77%.
Moving Average
TEKNA HOLDING’s worth is under its 50-day moving average of kr6.23 and way under its 200-day moving average of kr9.72.
Revenue Growth
Year-on-year quarterly revenue growth grew by 10.8%, now sitting on 27.66M for the twelve trailing months.
Volume
Today’s last reported volume for TEKNA HOLDING is 65100 which is 25.15% above its average volume of 52017.
Volatility
TEKNA HOLDING’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.55%, a negative 0.29%, and a positive 3.06%.
TEKNA HOLDING’s highest amplitude of average volatility was 1.55% (last week), 2.02% (last month), and 3.06% (last quarter).
More news about TEKNA HOLDING.
7. PIERRE VAC BSA ACT (VACBS.PA)
9.52% Price Change
CAC 40 ended the session with PIERRE VAC BSA ACT jumping 9.52% to €0.23 on Friday while CAC 40 rose 1.26% to €7,432.93.
Yearly Top and Bottom Value
PIERRE VAC BSA ACT’s stock is valued at €0.23 at 22:40 EST, below its 52-week low of €0.23.
More news about PIERRE VAC BSA ACT.
8. VALNEVA (VLA.PA)
8.48% Price Change
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.
CAC 40 ended the session with VALNEVA rising 8.48% to €5.68 on Friday while CAC 40 rose 1.26% to €7,432.93.
Earnings Per Share
As for profitability, VALNEVA has a trailing twelve months EPS of €-1.41.
Volatility
VALNEVA’s last week, last month’s, and last quarter’s current intraday variation average was 6.71%, 0.47%, and 2.29%.
VALNEVA’s highest amplitude of average volatility was 9.61% (last week), 3.26% (last month), and 2.29% (last quarter).
More news about VALNEVA.
9. VOLUE (VOLUE.OL)
8.38% Price Change
Volue ASA, together with its subsidiaries, engages in the provision of software and technology solutions for the energy, power grid, and infrastructure markets worldwide. It operates in three segments: Energy, Power Grid, and Infrastructure. The Energy segment offers software solutions and consulting services related to forecasting and optimization of the different energy markets that enables end-to-end optimization of the green energy value-chain. The Power Grid segment provides software solutions and consulting services that enables power distributors to support electrification of society by unlocking flexibility and digital management of the power grid. The Infrastructure segment offers software solutions and consulting services that delivers flexible solutions for digital water management. This segment is also involved in the automation of processes and machines for the construction industry. Volue ASA was incorporated in 2019 and is headquartered in Oslo, Norway. Volue ASA operates as a subsidiary of Arendals Fossekompani ASA.
Oslo Børs Benchmark Index_GI ended the session with VOLUE jumping 8.38% to €20.05 on Friday while Oslo Børs Benchmark Index_GI jumped 1.25% to €1,204.54.
Earnings Per Share
As for profitability, VOLUE has a trailing twelve months EPS of kr0.13.
PE Ratio
VOLUE has a trailing twelve months price to earnings ratio of 154.23. Meaning, the purchaser of the share is investing kr154.23 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.4%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 2.2%, now sitting on 1.22B for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, VOLUE’s stock is considered to be oversold (<=20).
More news about VOLUE.
10. MEDINCELL (MEDCL.PA)
7.32% Price Change
MedinCell S.A. develops various therapeutic solutions in France. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a risperidone extended-release injectable suspension completed Phase III trial for use in the treatment of schizophrenia; mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain & inflammation; and mdc-TJK, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials, such as mdc-ANG, an antipsychotic product for use in the treatment of schizophrenia; mdc-TTG for Covid-19 and its variants; mdc-GRT for use in organ transplant; mdc-WWM for contraception; mdc-STM for use in malaria; mdc-KPT for use in acute pain for pets; and mdc-IRM for use in neuroscience. The company was incorporated in 2003 and is based in Jacou, France.
CAC 40 ended the session with MEDINCELL jumping 7.32% to €8.94 on Friday, after two successive sessions in a row of losses. CAC 40 jumped 1.26% to €7,432.93, following the last session’s downward trend on what was an all-around up trend trading session today.
Earnings Per Share
As for profitability, MEDINCELL has a trailing twelve months EPS of €-1.12.
More news about MEDINCELL.
Losers Today
1. NR21 (NR21.PA)
-14% Price Change
NR21 Société Anonyme does not have significant operations. Previously, it was involved in design and distribution of underwear and indoor clothing for men, women, and children. The company is based in Paris, France.
CAC 40 ended the session with NR21 dropping 14% to €86.00 on Friday, after five sequential sessions in a row of losses. CAC 40 jumped 1.26% to €7,432.93, following the last session’s downward trend on what was an all-around positive trend trading session today.
Earnings Per Share
As for profitability, NR21 has a trailing twelve months EPS of €-1.36.
Volume
Today’s last reported volume for NR21 is 55 which is 2650% above its average volume of 2.
More news about NR21.
2. DISRUPTIVE CAP SHA (DCACS.AS)
-9.46% Price Change
Disruptive Capital Acquisition Company Limited does not have significant operations. It intends to complete a merger, amalgamation, share exchange, asset and/or liability acquisition, share purchase, reorganization, or related business combination with a target business or entity operating in the financial services sector. The company was incorporated in 2021 and is based in Saint Peter Port, Guernsey.
AEX-Index ended the session with DISRUPTIVE CAP SHA sliding 9.46% to €6.70 on Friday, after five consecutive sessions in a row of losses. AEX-Index rose 1.25% to €750.48, after three sequential sessions in a row of losses, on what was an all-around up trend exchanging session today.
More news about DISRUPTIVE CAP SHA.
3. SPORTING (SCP.LS)
-7.64% Price Change
Sporting Clube de Portugal – Futebol, SAD operates sports clubs in Portugal. The company also engages in the sale of tickets for games; advertising and sponsorships activities; and provision of television rights. Sporting Clube de Portugal – Futebol, SAD was founded in 1907 and is headquartered in Lisbon, Portugal.
PSI ended the session with SPORTING sliding 7.64% to €0.73 on Friday while PSI rose 0.37% to €6,112.95.
Earnings Per Share
As for profitability, SPORTING has a trailing twelve months EPS of €0.54.
PE Ratio
SPORTING has a trailing twelve months price to earnings ratio of 1.34. Meaning, the purchaser of the share is investing €1.34 for every euro of annual earnings.
Volume
Today’s last reported volume for SPORTING is 22 which is 95.69% below its average volume of 511.
More news about SPORTING.
4. SEABIRD EXPLORAT (SBX.OL)
-7.04% Price Change
SeaBird Exploration Plc, together with its subsidiaries, provides marine 2D and 3D seismic data for the oil and gas industry in Europe, Africa, the Middle East, North and South America, and the Asia Pacific. The company offers 2D seismic, and 3D and 3D shallow water acquisition services; and source vessels that provide conventional undershoot, 4D repeat survey, wide azimuth, push reverse, long-term charter and vessel management, in-house source modelling and environmental decay analysis, and spot charter services. It also engages in the marine minerals business. The company was founded in 1996 and is based in Nicosia, Cyprus.
Oslo Børs Benchmark Index_GI ended the session with SEABIRD EXPLORAT sliding 7.04% to €3.70 on Friday while Oslo Børs Benchmark Index_GI jumped 1.25% to €1,204.54.
Earnings Per Share
As for profitability, SEABIRD EXPLORAT has a trailing twelve months EPS of kr-1.05.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -30.6%.
More news about SEABIRD EXPLORAT.
5. HOFSETH BIOCARE (HBC.OL)
-6.98% Price Change
Hofseth BioCare ASA operates as a consumer and pet health ingredient supplier in Norway and internationally. Its products include Brilliant salmon oil; OmeGo salmon oil for the maintenance of healthy cholesterol, joint, eye, brain, and cardiovascular function; ProGo, a salmon protein hydrolysate powder for treatment of irondeficiency anaemia, irritable bowel syndrome, and sarcopenia; CalGo, a marine calcium powder produced to support cartilage function, joint health, and bone strength; CollaGo; and PetGo, a non-soluble protein. Hofseth BioCare ASA was incorporated in 2009 and is headquartered in Ålesund, Norway.
Oslo Børs Benchmark Index_GI ended the session with HOFSETH BIOCARE sliding 6.98% to €3.20 on Friday, following the last session’s upward trend. Oslo Børs Benchmark Index_GI jumped 1.25% to €1,204.54, after three sequential sessions in a row of losses, on what was an all-around positive trend trading session today.
Earnings Per Share
As for profitability, HOFSETH BIOCARE has a trailing twelve months EPS of kr-0.38.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -95.28%.
Volatility
HOFSETH BIOCARE’s last week, last month’s, and last quarter’s current intraday variation average was 0.60%, 1.30%, and 2.95%.
HOFSETH BIOCARE’s highest amplitude of average volatility was 1.49% (last week), 2.76% (last month), and 2.95% (last quarter).
Revenue Growth
Year-on-year quarterly revenue growth grew by 28.9%, now sitting on 120.45M for the twelve trailing months.
Volume
Today’s last reported volume for HOFSETH BIOCARE is 124497 which is 11.5% above its average volume of 111650.
More news about HOFSETH BIOCARE.
6. GEOJUNXION (GOJXN.AS)
-6.36% Price Change
GeoJunxion N.V. manufactures and supplies digital maps, premium location content, and location intelligence services worldwide. The company provides location aware content products, including Digital Maps for use in routing, planning, and display services; Geo Location application programming interface (API) that addresses geocoding and time zones covering Europe and North America; and Geo Planning API, which provides time and distance matrices for logistics and resource planning applications, as well as premium location content products, such as Safety Alert Zone that concentrates on road safety by alerting mobility users; Eco Alert Zones, which includes dataset of regulated congestion, emission and restricted traffic zones for use in routing, planning, fleet management, display, real estate applications, and other sectors; and Health Alert Zones that contains COVID-19 related information. It also offers location intelligence services, which includes search and evaluation of location enabled content to enhance existing maps and/or routing applications; creating bespoke datasets; and producing outdoor venue plans for use in events, travel and tourism, real estate applications, last mile navigation and delivery, retail and distribution, and smart city applications, as well as operates GeoAlertsLive application. The company was formerly known as AND International Publishers N.V. GeoJunxion N.V. was founded in 1984 and is headquartered in Capelle aan den IJssel, the Netherlands.
AEX-Index ended the session with GEOJUNXION sliding 6.36% to €1.11 on Friday, after two consecutive sessions in a row of gains. AEX-Index jumped 1.25% to €750.48, after three successive sessions in a row of losses, on what was an all-around positive trend trading session today.
Earnings Per Share
As for profitability, GEOJUNXION has a trailing twelve months EPS of €-0.2.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -0.3%.
Moving Average
GEOJUNXION’s worth is way under its 50-day moving average of €1.33 and way under its 200-day moving average of €1.56.
Volume
Today’s last reported volume for GEOJUNXION is 935 which is 79.59% below its average volume of 4583.
Revenue Growth
Year-on-year quarterly revenue growth grew by 45.5%, now sitting on 1.04M for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GEOJUNXION’s stock is considered to be oversold (<=20).
More news about GEOJUNXION.
7. RALLYE (RAL.PA)
-5.73% Price Change
Rallye SA, together with its subsidiaries, engages in the food and non-food e-commerce retailing business in France and internationally. The company operates in two segments, Food and General Retailing, and Holdings and Other Activities. It operates hypermarkets, supermarkets, and convenience stores. The company conducts its retailing activities in France primarily under the Casino, Monoprix, and Franprix banners; food retail activities in Latin America mainly under the GPA food banners, Éxito, Disco-Devoto, and Libertad banners; and e-commerce comprising Cdiscount and the Cnova N.V. holding company businesses. It is also involved in the financial investment and management, property development, and energy related activities. The company was founded in 1925 and is headquartered in Paris, France. As of December 31, 2021, Rallye SA operates as a subsidiary of Foncière Euris SA.
CAC 40 ended the session with RALLYE sliding 5.73% to €1.25 on Friday, after three successive sessions in a row of losses. CAC 40 jumped 1.26% to €7,432.93, following the last session’s downward trend on what was an all-around positive trend trading session today.
Earnings Per Share
As for profitability, RALLYE has a trailing twelve months EPS of €-4.45.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -9.93%.
Yearly Top and Bottom Value
RALLYE’s stock is valued at €1.25 at 22:40 EST, way below its 52-week high of €4.50 and higher than its 52-week low of €1.23.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, RALLYE’s stock is considered to be overbought (>=80).
Moving Average
RALLYE’s worth is way below its 50-day moving average of €2.02 and way under its 200-day moving average of €2.67.
More news about RALLYE.
8. BAKKAFROST (BAKKA.OL)
-5.67% Price Change
P/F Bakkafrost, together with its subsidiaries, produces and sells salmon products under the Bakkafrost and Havsbrún brands in North America, Western Europe, Eastern Europe, Asia, and internationally. It operates through four segments: Farming FO; Farming SCT; Value Added Products; and Fishmeal, Oil and Fish Feed. The company is involved in the breeding and on-growing of salmon; harvesting, sale, and distribution of salmon; salmon farming, harvest, filleting, sales, and administration; and production of skinless and boneless portions of salmon. It also produces and sells fishmeal, fish oil, and fish feed. In addition, it engages in production of styrofoam boxes, and biogas and fertilizer; and operates trading of fishes, lumpfish farming business, and freight transportation of goods, as well as produce and sell canned fish products. P/F Bakkafrost was founded in 1968 and is headquartered in Glyvrar, Denmark.
Oslo Børs Benchmark Index_GI ended the session with BAKKAFROST sliding 5.67% to €716.00 on Friday, after two consecutive sessions in a row of gains. Oslo Børs Benchmark Index_GI jumped 1.25% to €1,204.54, after three successive sessions in a row of losses, on what was an all-around up trend trading session today.
Earnings Per Share
As for profitability, BAKKAFROST has a trailing twelve months EPS of kr36.54.
PE Ratio
BAKKAFROST has a trailing twelve months price to earnings ratio of 19.59. Meaning, the purchaser of the share is investing kr19.59 for every norwegian krone of annual earnings.
Volume
Today’s last reported volume for BAKKAFROST is 83349 which is 41.23% above its average volume of 59013.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BAKKAFROST’s stock is considered to be oversold (<=20).
More news about BAKKAFROST.
9. CARASENT (CARA.OL)
-5.47% Price Change
Carasent ASA provides cloud-based medical record services to the health care industry in the Nordic region. The company offers Webdoc, a digital electronic health record (EHR) system; Vårdrummet, a digital platform for communication between patients and therapists, as well as care givers; and Ad Curis, a journal and professional system that delivers forward-thinking services to rehabilitation, substance abuse treatment, and mental health care, as well as organizations within upbringing and preventive works. It also provides Metodika EPM, a solution for medium sized private clinics and hospitals; Medrave M4, a program that offers healthcare professionals with an overview of the patient treatment group; Confrere, a video solution for physicians; and Plustoo, a software solution that collects, analyses, and visualizes data, as well as enables occupational health providers, employers, and employees to collaborate for healthy and sustainable work environment. In addition, the company provides Ad Voca; and Ad Opus, a system that structures work processes to follow-up participants in a course of measures for companies that work with inclusion into working life. Carasent ASA was formerly known as Apptix ASA and changed its name to Carasent ASA in May 2019. The company was founded in 1997 and is based in Oslo, Norway.
Oslo Børs Benchmark Index_GI ended the session with CARASENT dropping 5.47% to €14.86 on Friday, following the last session’s downward trend. Oslo Børs Benchmark Index_GI jumped 1.25% to €1,204.54, after three consecutive sessions in a row of losses, on what was an all-around positive trend trading session today.
Earnings Per Share
As for profitability, CARASENT has a trailing twelve months EPS of kr0.38.
PE Ratio
CARASENT has a trailing twelve months price to earnings ratio of 39.11. Meaning, the purchaser of the share is investing kr39.11 for every norwegian krone of annual earnings.
Volatility
CARASENT’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.51%, a positive 0.09%, and a positive 2.10%.
CARASENT’s highest amplitude of average volatility was 7.13% (last week), 2.31% (last month), and 2.10% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, CARASENT’s stock is considered to be overbought (>=80).
More news about CARASENT.
10. AF GRUPPEN (AFG.OL)
-5.32% Price Change
AF Gruppen ASA, a contracting and industrial company, engages in civil engineering, construction, property, energy, environment, and offshore businesses primarily in Norway and Sweden. The company's Civil Engineering business area undertakes civil engineering and niche projects related to roads and railways, port facilities, airports, tunnels, foundation work, power, and energy, as well as onshore facilities for oil and gas. Its Construction business area develops, engineers, and constructs commercial, residential, and public buildings, as well as rehabilitation projects. The company's Betonmast business area operates as building contractor for large residential properties, and commercial and public buildings; and develops properties. Its Property business area develops residential units and commercial buildings. The company's Energy and Environment business area provides smart and energy efficient services for buildings and industry; and demolition and recycling services. Its Sweden business area engages in construction, civil engineering, property, and environmental activities. The company's offshore business area undertakes the removal, demolition, and recycling of offshore installations; and construction, modification, and maintenance works related to cranes, modules, and rig services, as well as heating, ventilation, air conditioning, and cooling systems. AF Gruppen ASA was founded in 1985 and is headquartered in Oslo, Norway.
Oslo Børs Benchmark Index_GI ended the session with AF GRUPPEN sliding 5.32% to €149.60 on Friday while Oslo Børs Benchmark Index_GI jumped 1.25% to €1,204.54.
Earnings Per Share
As for profitability, AF GRUPPEN has a trailing twelve months EPS of kr8.94.
PE Ratio
AF GRUPPEN has a trailing twelve months price to earnings ratio of 16.73. Meaning, the purchaser of the share is investing kr16.73 for every norwegian krone of annual earnings.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, AF GRUPPEN’s stock is considered to be overbought (>=80).
More news about AF GRUPPEN.
Stay up to date with our winners and losers daily report
